PL3789038T3 - Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 - Google Patents
Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47Info
- Publication number
- PL3789038T3 PL3789038T3 PL20198499.4T PL20198499T PL3789038T3 PL 3789038 T3 PL3789038 T3 PL 3789038T3 PL 20198499 T PL20198499 T PL 20198499T PL 3789038 T3 PL3789038 T3 PL 3789038T3
- Authority
- PL
- Poland
- Prior art keywords
- humanized
- monoclonal antibodies
- chimeric monoclonal
- chimeric
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39565210P | 2010-05-14 | 2010-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3789038T3 true PL3789038T3 (pl) | 2023-01-23 |
Family
ID=44915009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20198499.4T PL3789038T3 (pl) | 2010-05-14 | 2011-05-13 | Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9017675B2 (pl) |
| EP (4) | EP3181149A1 (pl) |
| JP (6) | JP6166177B2 (pl) |
| AU (5) | AU2011252851B2 (pl) |
| CA (2) | CA2797720C (pl) |
| DK (2) | DK2569013T3 (pl) |
| ES (2) | ES2937174T3 (pl) |
| HR (2) | HRP20170254T1 (pl) |
| HU (2) | HUE060541T2 (pl) |
| LT (1) | LT3789038T (pl) |
| PL (1) | PL3789038T3 (pl) |
| PT (2) | PT3789038T (pl) |
| WO (1) | WO2011143624A2 (pl) |
Families Citing this family (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4160212T1 (sl) | 2008-01-15 | 2024-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Označevalci matičnih celic akutne mieloične levkemije |
| PT3056515T (pt) * | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2995315B1 (en) | 2009-05-15 | 2023-12-27 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction |
| EP3181149A1 (en) | 2010-05-14 | 2017-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
| CN104271757B (zh) | 2012-02-06 | 2020-06-09 | 印希彼有限公司 | Cd47抗体及其使用方法 |
| US11059910B2 (en) | 2012-12-03 | 2021-07-13 | Novimmune Sa | Anti-CD47 antibodies and methods of use thereof |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| ES2786083T3 (es) * | 2012-12-12 | 2020-10-08 | Arch Oncology Inc | Anticuerpos terapéuticos CD47 |
| SI2931752T1 (sl) | 2012-12-17 | 2019-12-31 | Trillium Therapeutics Inc. | Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRP |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| EP3721888B1 (en) | 2013-02-05 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Cd47 targeted therapies for the treatment of infectious disease |
| SG11201506132PA (en) * | 2013-02-06 | 2015-09-29 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| AU2014244083B2 (en) * | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| ES2728066T3 (es) | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
| AU2014260245B2 (en) * | 2013-04-29 | 2020-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-CD47 agents to enhance immunization |
| JP6546178B2 (ja) | 2013-09-13 | 2019-07-17 | ジェネンテック， インコーポレイテッド | 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法 |
| AR097651A1 (es) | 2013-09-13 | 2016-04-06 | Genentech Inc | Métodos y composiciones que comprenden polipéptidos recombinantes purificados |
| US10329354B2 (en) * | 2013-09-18 | 2019-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| WO2015105995A2 (en) | 2014-01-08 | 2015-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| WO2015161267A2 (en) | 2014-04-18 | 2015-10-22 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd99 |
| PT3180363T (pt) | 2014-08-15 | 2019-11-05 | Merck Patent Gmbh | Proteínas de fusão de sirp-alfa e imunoglobulina |
| LT3656869T (lt) | 2014-08-26 | 2021-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Kamieninių ląstelių įtvirtinimas su agento, nukreipto į kamienines ląsteles, kompozicija ir imunoreguliacinio signalo moduliavima |
| ES2822561T3 (es) | 2014-09-15 | 2021-05-04 | Univ Leland Stanford Junior | Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis |
| AU2015329696A1 (en) | 2014-10-10 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting CD47 |
| ES2822228T3 (es) | 2014-10-24 | 2021-04-29 | Univ Leland Stanford Junior | Composiciones y métodos para inducir la fagocitosis de células positivas de clase I de CMH y contrarrestar la resistencia a anti-CD47/SIRPA |
| WO2016081423A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| CA2972913A1 (en) | 2015-01-21 | 2016-07-28 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| ES2838925T3 (es) | 2015-02-27 | 2021-07-02 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
| TWI778518B (zh) * | 2015-03-04 | 2022-09-21 | 美商索倫多醫療公司 | 結合cd47之抗體治療劑 |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| HUE055139T2 (hu) | 2015-08-07 | 2021-11-29 | Alx Oncology Inc | A SIRP-alfa domént vagy ennek variánsát tartalmazó készítmények |
| PL3341015T5 (pl) | 2015-08-26 | 2024-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Zwiększona deplecja komórek docelowych z blokadą cd47 i immunologicznym agonistą kostymulatorowym |
| EP3349787A4 (en) | 2015-09-18 | 2019-03-27 | Arch Oncology, Inc. | THERAPEUTIC CD47 ANTIBODIES |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| EA201891093A1 (ru) | 2015-11-03 | 2018-10-31 | Янссен Байотек, Инк. | Антитела, специфически связывающие pd-1, и их применение |
| US11400145B2 (en) | 2015-11-27 | 2022-08-02 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
| CN115569192A (zh) | 2015-12-11 | 2023-01-06 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
| PT3402820T (pt) | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| EP3405499A4 (en) | 2016-01-21 | 2020-03-18 | The Board of Trustees of the Leland Stanford Junior University | TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORS |
| PT3442578T (pt) | 2016-04-15 | 2022-05-19 | Univ Leland Stanford Junior | Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancro |
| US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| US11142548B2 (en) | 2016-05-10 | 2021-10-12 | Sorbonne Universite | Agents that activate CD47 and their use in the treatment of inflammation |
| CN106117354B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
| WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
| US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| AU2017307198B2 (en) | 2016-08-03 | 2024-05-30 | Forty Seven, LLC | Disrupting Fc receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy |
| CN108738313B (zh) | 2016-10-20 | 2022-12-30 | 天境生物科技(上海)有限公司 | 新的cd47单克隆抗体及其应用 |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| ES2987333T3 (es) | 2016-10-26 | 2024-11-14 | Univ Leland Stanford Junior | Regiones bisagra de inmunoglobulina modificadas para reducir la hemaglutinación |
| EP3534964A4 (en) | 2016-11-03 | 2020-07-15 | Trillium Therapeutics Inc. | IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS |
| US11352425B2 (en) | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| CN108779179B (zh) * | 2016-11-28 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | Cd47抗体、其抗原结合片段及其医药用途 |
| EP3345924A1 (en) | 2017-01-10 | 2018-07-11 | Universität Duisburg-Essen | Use of cd47 antibodies |
| KR102607101B1 (ko) * | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
| BR112019015342A2 (pt) | 2017-01-30 | 2020-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Regime de condicionamento não genotóxico para o transplante de células-tronco |
| WO2018152033A1 (en) | 2017-02-14 | 2018-08-23 | Promab Biotechnologies, Inc. | Cd47-car-t cells |
| CN108424461B (zh) * | 2017-02-14 | 2023-03-31 | 亘喜生物科技（上海）有限公司 | Cd47-car-t细胞 |
| CA3053392A1 (en) | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of cd47 blockade |
| US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
| US20190062428A1 (en) | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
| SI3642242T1 (sl) | 2017-06-21 | 2024-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti |
| US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| SG11202000053TA (en) | 2017-08-02 | 2020-02-27 | Phanes Therapeutics Inc | Anti-cd47 antibodies and uses thereof |
| JP7256580B2 (ja) | 2017-08-18 | 2023-04-12 | ウルトラヒューマン フォー リミティド | 結合剤 |
| CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| ES2989007T3 (es) | 2017-10-18 | 2024-11-25 | Forty Seven Llc | Terapia contra el cáncer de ovarios basada en agente anti-CD47 |
| KR20200070341A (ko) | 2017-10-18 | 2020-06-17 | 포티 세븐, 인코포레이티드 | 항-cd47 및 항-pd-l1로 난소암의 치료 |
| CN111448213A (zh) | 2017-12-01 | 2020-07-24 | 西雅图基因公司 | Cd47抗体及其用于治疗癌症的用途 |
| WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
| KR20250057146A (ko) | 2018-01-12 | 2025-04-28 | 오리진 온콜로지 리미티드 | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| EP4129336B1 (en) | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| WO2019200357A1 (en) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarker for cd47 targeting therapeutics and uses therefor |
| CN110538321B (zh) * | 2018-05-29 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 一种cd47抗体药物组合物及其用途 |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| JP7468903B2 (ja) | 2018-06-17 | 2024-04-16 | エルアンドエル バイオファーマ カンパニー リミテッド | Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用 |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| MX2020013068A (es) | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CA3110620C (en) | 2018-08-31 | 2023-06-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47 antibody and application thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3876931A1 (en) | 2018-11-08 | 2021-09-15 | Aurigene Discovery Technologies Limited | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
| ES2988145T3 (es) | 2018-11-26 | 2024-11-19 | Forty Seven Inc | Anticuerpos humanizados contra c-kit |
| KR20210094609A (ko) | 2018-11-28 | 2021-07-29 | 포티 세븐, 인코포레이티드 | 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc |
| CN113166257B (zh) | 2018-12-03 | 2023-05-30 | 上海开拓者生物医药有限公司 | Cd47抗体及其制备方法和应用 |
| US20220143180A1 (en) * | 2019-02-26 | 2022-05-12 | Innovent Biologics (Suzhou) Co., Ltd. | Formulation comprising anti-cd47 antibody, preparation method therefor and use thereof |
| CN112969719B (zh) | 2019-03-06 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
| KR20210143868A (ko) * | 2019-03-26 | 2021-11-29 | 포티 세븐, 인코포레이티드 | 암 치료용 다중특이성 제제 |
| CN113692413A (zh) * | 2019-04-02 | 2021-11-23 | 肯乔克蒂生物技术股份有限公司 | 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法 |
| CN110003335B (zh) * | 2019-04-12 | 2023-07-04 | 深圳普瑞金生物药业股份有限公司 | Cd47单域抗体、核酸及试剂盒 |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| WO2020247572A1 (en) * | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Masked antibody formulations |
| WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4003375A4 (en) * | 2019-07-31 | 2023-09-06 | Forty Seven, Inc. | DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY |
| CN112442123B (zh) | 2019-09-03 | 2022-08-23 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
| EP4013512B1 (en) | 2019-09-18 | 2024-02-14 | LamKap Bio alpha AG | Bispecific antibodies against ceacam5 and cd3 |
| CN112646038B (zh) | 2019-10-11 | 2025-06-03 | 迈威(上海)生物科技股份有限公司 | 抗人Trop-2抗体及其应用 |
| WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| ES3001984T3 (en) | 2019-12-24 | 2025-03-06 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| JP2023509083A (ja) | 2020-01-09 | 2023-03-06 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 腫瘍を予防又は治療するための薬物の調製における抗ｃｄ４７抗体と抗ｃｄ２０抗体の組み合わせの使用 |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| WO2021170772A1 (en) | 2020-02-26 | 2021-09-02 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling |
| US20230090014A1 (en) | 2020-02-28 | 2023-03-23 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47/anti-pd-l1 antibody and applications thereof |
| CA3172449A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN113461817B (zh) | 2020-03-31 | 2025-04-18 | 苏州泽璟生物制药股份有限公司 | 一种抗人cd47抗体及其抗原结合片段、制备方法和应用 |
| AU2021250200A1 (en) | 2020-04-02 | 2022-12-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antigen-binding polypeptide binding to CD47, and use thereof |
| TW202216193A (zh) | 2020-06-22 | 2022-05-01 | 德商莫菲西斯公司 | 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法 |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| JP2023550544A (ja) | 2020-11-03 | 2023-12-01 | アールディスカバリー エルエルシー | がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法 |
| JP2023551113A (ja) | 2020-11-06 | 2023-12-07 | バイオ－テラ ソリュ－ションズ，エルティーディー． | 二重特異性抗体及びその応用 |
| WO2022100694A1 (zh) | 2020-11-12 | 2022-05-19 | 迈威(上海)生物科技股份有限公司 | 抗体及其制备方法 |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| JP7454044B2 (ja) | 2020-12-23 | 2024-03-21 | グアンドン ファポン バイオファーマ インコーポレイテッド | Ｃｄ４７を標的とする抗体及びその使用 |
| AU2022222994B2 (en) | 2021-02-19 | 2025-11-27 | Shaperon Inc. | Single domain antibody against cd47 and use thereof |
| MX2023009715A (es) | 2021-02-19 | 2024-01-08 | Shaperon Inc | Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo. |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP7556468B2 (ja) | 2021-06-10 | 2024-09-26 | 小野薬品工業株式会社 | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7654118B2 (ja) | 2021-06-23 | 2025-03-31 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024527551A (ja) | 2021-06-29 | 2024-07-25 | シージェン インコーポレイテッド | 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法 |
| CN115702931A (zh) | 2021-08-06 | 2023-02-17 | 百奥泰生物制药股份有限公司 | 抗pd-l1/cd47双特异抗体在治疗疾病中的应用 |
| CN115925940A (zh) * | 2021-08-24 | 2023-04-07 | 上海鑫湾生物科技有限公司 | 特异性结合cd47的抗体、其重组溶瘤病毒及其用途 |
| AR127270A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Formulación de anticuerpos anti-cd47 |
| CN115991784A (zh) | 2021-10-19 | 2023-04-21 | 宝船生物医药科技(上海)有限公司 | 抗cd47-cldn18.2双特异性抗体及其用途 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| KR102876945B1 (ko) | 2021-11-19 | 2025-10-29 | 한국과학기술연구원 | 표적 세포로의 활성 제약 성분의 적혈구-매개 전달을 위한 치료 화합물 |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024546851A (ja) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| WO2023122882A1 (zh) | 2021-12-27 | 2023-07-06 | 上海鑫湾生物科技有限公司 | 双特异性t细胞衔接器、其重组溶瘤病毒及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4479084A1 (en) | 2022-02-14 | 2024-12-25 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| CN114573710A (zh) * | 2022-02-16 | 2022-06-03 | 南方医科大学珠江医院 | 一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| WO2023224412A1 (ko) | 2022-05-19 | 2023-11-23 | (주)샤페론 | Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| AU2023307100A1 (en) | 2022-07-12 | 2025-01-02 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4601692A1 (en) * | 2022-10-14 | 2025-08-20 | Nanjing Legend Biotech Co., Ltd. | Antibodies targeting cd47 and uses thereof |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN116836290B (zh) * | 2023-01-04 | 2024-10-22 | 科弈(浙江)药业科技有限公司 | 针对pd-l1和cd47的双特异性抗体、其制备方法及其用途 |
| WO2024146553A1 (en) * | 2023-01-04 | 2024-07-11 | Wuxi Biologics (Shanghai) Co., Ltd. | Antibodies against cd47, method for preparing the same, and use thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| AU2024259556A1 (en) | 2023-04-21 | 2025-10-23 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1549776A (en) | 1975-08-07 | 1979-08-08 | Girling Ltd | Double acting valved pistons |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS5547656U (pl) | 1978-09-22 | 1980-03-28 | ||
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5057604A (en) * | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH0747841B2 (ja) | 1991-02-15 | 1995-05-24 | ゼニヤ海洋サービス株式会社 | 浮体の自沈装置 |
| ATE188708T1 (de) * | 1991-08-21 | 2000-01-15 | Novartis Ag | Antikörperderivate |
| US5792852A (en) * | 1992-11-16 | 1998-08-11 | Cancer Research Fund Of Contra Costa | Polynucleotides encoding modified antibodies with human milk fat globule specificity |
| US6986890B1 (en) * | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
| US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6491917B1 (en) | 1998-07-31 | 2002-12-10 | Stemcell Technologies Inc. | Antibody composition for debulking blood and bone marrow samples from CML patients |
| EP1109937B1 (en) * | 1998-09-02 | 2008-11-05 | Diadexus, Inc. | METHOD OF DIAGNOSING, MONITORING, STAGING, and IMAGING VARIOUS CANCERS |
| AU1208200A (en) * | 1998-10-15 | 2000-05-01 | Genetics Institute Inc. | Secreted expressed sequence tags (sests) |
| US20030096976A1 (en) * | 1998-11-17 | 2003-05-22 | Hong Hyo Jeong | Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies |
| WO2000053634A1 (en) * | 1999-03-10 | 2000-09-14 | Chugai Seiyaku Kabushiki Kaisha | Single-stranded fv inducing apoptosis |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| DK1194035T3 (da) | 1999-06-29 | 2008-01-28 | Univ Leland Stanford Junior | Delmængder af myeloide progenitorceller i pattedyr |
| WO2001066139A1 (en) | 2000-03-06 | 2001-09-13 | University Of Kentucky Research Foundation | Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| US6838250B2 (en) * | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| CN1308447C (zh) * | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | 低分子化的激动剂抗体 |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| EP1455820A2 (en) | 2001-03-09 | 2004-09-15 | William Herman | Targeted ligands |
| US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| JP3632668B2 (ja) | 2002-02-18 | 2005-03-23 | ミノルタ株式会社 | デジタルカメラ |
| JP4432031B2 (ja) * | 2002-03-22 | 2010-03-17 | ズィナイス オペレーションズ ピーティーワイ．エルティーディー． | インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体 |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2005044857A1 (ja) | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | ヒト化抗cd47抗体 |
| WO2005054469A1 (en) * | 2003-12-05 | 2005-06-16 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
| WO2005111623A1 (en) | 2004-05-17 | 2005-11-24 | Crucell Holland B.V. | Methods for diagnosis of acute myeloid leukemia |
| US20090202986A1 (en) * | 2004-10-22 | 2009-08-13 | Huse William D | Methods of optimizing antibody variable region binding affinity |
| CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| CA2613818C (en) * | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI1915397T1 (sl) * | 2005-08-19 | 2015-05-29 | Wyeth Llc | Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8 |
| CA2620802A1 (en) * | 2005-08-31 | 2007-03-08 | Schering Corporation | Engineered anti-il-23 antibodies |
| US20070113297A1 (en) | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| CA2622760C (en) | 2005-09-16 | 2012-12-04 | Janssen Pharmaceutica N.V. | Cyclopropyl amines as modulators of the histamine h3 receptor |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| WO2007064919A2 (en) * | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AU2007249709A1 (en) * | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| WO2008008515A2 (en) * | 2006-07-14 | 2008-01-17 | Aviva Biosciences Corporation | Methods and compositions for detecting rare cells from a biological sample |
| CN101534848B (zh) * | 2006-09-19 | 2013-07-17 | 亚洲大学校产学协力团 | 抗动物病毒的抗病毒剂 |
| EP2097535B1 (en) | 2006-12-07 | 2016-09-21 | The Board of Trustees of the Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| US8026345B2 (en) * | 2007-01-08 | 2011-09-27 | Hoffmann-La Roche Inc. | Characterization and identification of unique human adiponectin isoforms and antibodies |
| JP4453724B2 (ja) | 2007-06-29 | 2010-04-21 | 株式会社デンソー | 車両用冷凍サイクル装置 |
| AU2008282863A1 (en) * | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| KR101710472B1 (ko) * | 2007-11-30 | 2017-02-27 | 글락소 그룹 리미티드 | 항원-결합 작제물 |
| PT3056515T (pt) * | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| AU2009279676C1 (en) * | 2008-08-07 | 2015-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Radioprotectants targeting thrombospondin-1 and CD47 |
| JP5671050B2 (ja) | 2009-11-04 | 2015-02-18 | エスティー‐エリクソン（フランス）エスエーエスＳｔ−Ｅｒｉｃｓｓｏｎ （Ｆｒａｎｃｅ） Ｓａｓ | ランダムアクセスメモリの動的管理 |
| EP3181149A1 (en) * | 2010-05-14 | 2017-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
-
2011
- 2011-05-13 EP EP16200105.1A patent/EP3181149A1/en not_active Ceased
- 2011-05-13 EP EP23214925.2A patent/EP4349868A3/en active Pending
- 2011-05-13 DK DK11781385.7T patent/DK2569013T3/da active
- 2011-05-13 PT PT201984994T patent/PT3789038T/pt unknown
- 2011-05-13 JP JP2013510355A patent/JP6166177B2/ja active Active
- 2011-05-13 HR HRP20170254TT patent/HRP20170254T1/hr unknown
- 2011-05-13 DK DK20198499.4T patent/DK3789038T3/da active
- 2011-05-13 HU HUE20198499A patent/HUE060541T2/hu unknown
- 2011-05-13 HR HRP20221260TT patent/HRP20221260T1/hr unknown
- 2011-05-13 EP EP11781385.7A patent/EP2569013B1/en active Active
- 2011-05-13 EP EP20198499.4A patent/EP3789038B1/en active Active
- 2011-05-13 PL PL20198499.4T patent/PL3789038T3/pl unknown
- 2011-05-13 ES ES20198499T patent/ES2937174T3/es active Active
- 2011-05-13 AU AU2011252851A patent/AU2011252851B2/en active Active
- 2011-05-13 HU HUE11781385A patent/HUE031778T2/en unknown
- 2011-05-13 CA CA2797720A patent/CA2797720C/en active Active
- 2011-05-13 ES ES11781385.7T patent/ES2616010T3/es active Active
- 2011-05-13 CA CA3138956A patent/CA3138956A1/en active Pending
- 2011-05-13 PT PT117813857T patent/PT2569013T/pt unknown
- 2011-05-13 WO PCT/US2011/036535 patent/WO2011143624A2/en not_active Ceased
- 2011-05-13 LT LTEP20198499.4T patent/LT3789038T/lt unknown
-
2012
- 2012-11-13 US US13/675,274 patent/US9017675B2/en active Active
-
2015
- 2015-03-12 US US14/656,431 patent/US9382320B2/en active Active
-
2016
- 2016-06-07 US US15/175,848 patent/US20160304609A1/en not_active Abandoned
- 2016-08-08 JP JP2016156023A patent/JP6943549B2/ja active Active
- 2016-12-14 AU AU2016273893A patent/AU2016273893A1/en not_active Abandoned
-
2018
- 2018-06-20 AU AU2018204448A patent/AU2018204448A1/en not_active Abandoned
-
2019
- 2019-07-12 JP JP2019130492A patent/JP6964631B2/ja active Active
-
2020
- 2020-05-13 AU AU2020203132A patent/AU2020203132B2/en active Active
- 2020-12-01 US US17/108,731 patent/US11014985B2/en active Active
-
2021
- 2021-04-21 US US17/236,810 patent/US11807684B2/en active Active
- 2021-10-19 JP JP2021170804A patent/JP7199494B2/ja active Active
-
2022
- 2022-12-20 JP JP2022202871A patent/JP7412521B2/ja active Active
-
2023
- 2023-05-01 AU AU2023202660A patent/AU2023202660A1/en active Pending
- 2023-09-28 US US18/477,254 patent/US20240084006A1/en active Pending
- 2023-12-26 JP JP2023219295A patent/JP7763230B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3789038T3 (pl) | Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 | |
| LTC2785375I2 (lt) | Anti-pd-l1 antikūnai ir jų panaudojimas | |
| DK2521736T3 (da) | Humaniserede antistoffer | |
| HRP20181360T1 (hr) | Anti-cd28 humanizirana protutijela | |
| IL221408B (en) | Monoclonal antibodies against c-met | |
| DK3842456T3 (da) | Monoklonalt Interleukin-31-antistof | |
| SMT201700083B (it) | Anticorpi monoclonali | |
| BR112013032552A2 (pt) | variantes de anticorpos monoclonais humanizados imunomoduladores | |
| LT2975051T (lt) | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu | |
| BR112013022797A2 (pt) | anticorpos anti-ctla4 humanizados | |
| SMT201400184B (it) | Anticorpi monoclonali che legano b7h6 e loro usi | |
| BRPI0907532A2 (pt) | Anticorpos anti-c5ar humanizados | |
| HRP20181645T1 (hr) | Monoklonalna antitijela prema progastrinu i njihove upotrebe | |
| BR112013002297A2 (pt) | anticorpos humanizados seguros e funcionais | |
| HRP20180728T1 (hr) | Humanizirana protutijela koja prepoznaju alfa-sinuklein | |
| CR20170001A (es) | Anticuerpos anti factor d humanizados | |
| BRPI0908508A2 (pt) | anticorpo monoclonal nkg2a anti-humano humanizado | |
| EP2542258A4 (en) | MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52 | |
| DK3351255T3 (da) | Modificerede anti-cd4-antistoffer | |
| HUE036157T2 (hu) | Humanizált IL-25 ellenanyagok | |
| EP2545075A4 (en) | HUMANIZED AND CHIMERIC ANTIBODIES AGAINST PROPERDIN | |
| EP2542262A4 (en) | MONOCLONAL ANTIBODIES DIRECTED AGAINST CD20 | |
| EP2650367A4 (en) | HUMAN MONOCLONAL ANTIBODY | |
| HK40107903A (en) | Humanized and chimeric monoclonal antibodies to cd47 |